Literature DB >> 28052967

Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.

David M Lewinsohn1, Michael K Leonard2, Philip A LoBue3, David L Cohn4, Charles L Daley5, Ed Desmond6, Joseph Keane7, Deborah A Lewinsohn1, Ann M Loeffler8, Gerald H Mazurek3, Richard J O'Brien9, Madhukar Pai10, Luca Richeldi11, Max Salfinger12, Thomas M Shinnick3, Timothy R Sterling13, David M Warshauer14, Gail L Woods15.   

Abstract

BACKGROUND: Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuberculosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its diagnosis remain.
METHODS: A task force supported by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America searched, selected, and synthesized relevant evidence. The evidence was then used as the basis for recommendations about the diagnosis of tuberculosis disease and LTBI in adults and children. The recommendations were formulated, written, and graded using the Grading, Recommendations, Assessment, Development and Evaluation (GRADE) approach.
RESULTS: Twenty-three evidence-based recommendations about diagnostic testing for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis are provided. Six of the recommendations are strong, whereas the remaining 17 are conditional.
CONCLUSIONS: These guidelines are not intended to impose a standard of care. They provide the basis for rational decisions in the diagnosis of tuberculosis in the context of the existing evidence. No guidelines can take into account all of the often compelling unique individual clinical circumstances.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2017        PMID: 28052967      PMCID: PMC5504475          DOI: 10.1093/cid/ciw778

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  140 in total

Review 1.  Medical management of drug-sensitive active thoracic tuberculosis: the work-up, radiographic findings and treatment.

Authors:  Jared Eddy; Taimur Khan; Frank Schembri
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Evaluation of the Xpert MTB/RIF Ultra Assay for Direct Detection of Mycobacterium tuberculosis Complex in Smear-Negative Extrapulmonary Samples.

Authors:  Daniel Perez-Risco; David Rodriguez-Temporal; Ivan Valledor-Sanchez; Fernando Alcaide
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

3.  Laboratory Cross-Contamination of Mycobacterium tuberculosis: A Systematic Review and Meta-analysis.

Authors:  Aleksandra Barac; Hannah Karimzadeh-Esfahani; Mahya Pourostadi; Mohammad Taghi Rahimi; Ehsan Ahmadpour; Jalil Rashedi; Behroz Mahdavipoor; Hossein Samadi Kafil; Adel Spotin; Kalkidan Hassen Abate; Alexander G Mathioudakis; Mohammad Asgharzadeh
Journal:  Lung       Date:  2019-06-15       Impact factor: 2.584

4.  Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.

Authors:  Ravy K Vajravelu; Mark T Osterman; Faten N Aberra; Jason A Roy; Gary R Lichtenstein; Ronac Mamtani; David S Goldberg; James D Lewis; Frank I Scott
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

5.  Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.

Authors:  Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

6.  Multiplex Real-Time PCR-shortTUB Assay for Detection of the Mycobacterium tuberculosis Complex in Smear-Negative Clinical Samples with Low Mycobacterial Loads.

Authors:  Fernando Alcaide; Rocío Trastoy; Raquel Moure; Mónica González-Bardanca; Antón Ambroa; María López; Inés Bleriot; Lucia Blasco; Laura Fernandez-García; Marta Tato; German Bou; María Tomás
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

7.  Capsular glycan recognition provides antibody-mediated immunity against tuberculosis.

Authors:  Tingting Chen; Caroline Blanc; Yanyan Liu; Elise Ishida; Sarah Singer; Jiayong Xu; Maju Joe; Elizabeth R Jenny-Avital; John Chan; Todd L Lowary; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 8.  Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV.

Authors:  Stephanie Bjerrum; Ian Schiller; Nandini Dendukuri; Mikashmi Kohli; Ruvandhi R Nathavitharana; Alice A Zwerling; Claudia M Denkinger; Karen R Steingart; Maunank Shah
Journal:  Cochrane Database Syst Rev       Date:  2019-10-21

9.  Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study.

Authors:  Víctor Vinuesa; Rafael Borrás; María Luisa Briones; María Ángeles Clari; Vicenta Cresencio; Estela Giménez; Carmen Muñoz; Rosa Oltra; Emilio Servera; Talia Scheelje; Carlos Tornero; David Navarro
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

10.  Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.

Authors:  Elitza S Theel; Heather Hilgart; Margaret Breen-Lyles; Kevin McCoy; Rhiannon Flury; Laura E Breeher; John Wilson; Irene G Sia; Jennifer A Whitaker; Jeremy Clain; Timothy R Aksamit; Patricio Escalante
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.